Release date: 2007-08-17
In a groundbreaking development, U.S. scientists have created a new tool designed to detect bacterial membranes more effectively. This innovative cross-flow analysis device was developed in collaboration between students from the University of Northern Arizona and the University of Maryland. The technology works by identifying biofilm-specific antibodies present in a patient's bloodstream, using a method similar to how streptococcal infections are diagnosed. This advancement could significantly improve early detection and treatment of biofilm-related infections.
Bacteria often form clusters known as "micro-clones," where the bacteria themselves make up less than one-third of the total volume. The rest of the space is filled with a sticky substance called the "extracellular matrix," which is secreted by the bacteria. This viscous material acts like a glue, holding thousands of micro-clones together to create a protective structure known as a biofilm.
It's estimated that around 70% of bacterial infections are linked to biofilms. These structures are highly resistant to antibiotics and the body’s natural defenses. Once a biofilm forms at an infection site, even high doses of medication may struggle to eliminate it, making these infections particularly challenging to treat. This resistance plays a key role in the persistence of chronic and difficult-to-treat infections. According to the U.S. Centers for Disease Control and Prevention, the annual cost of treating such diseases in the U.S. reaches approximately $5 billion.
Jeff Laide, a researcher from the Center for Microbial Genetics at the University of Northern Arizona, stated, “Previously, healthcare professionals lacked a reliable method to diagnose these infections, which often led to delayed treatments. Now, we believe this issue can be addressed.†The research team is currently finalizing the details of the device and seeking partnerships with companies interested in commercializing the technology. Their goal is to bring this tool to market as a widely available medical device, helping improve patient outcomes globally.
—— Information from: China Medical Device NetworkUlcers is commonly known as gastric ulcer and duodenal ulcer, the formation of ulcers is closely related with gastric acid or pepsin digestion. Ulcer disease is a chronic disease, its seizures were cyclical, episodes and remission of alternating appear, and the onset of abdominal pain has a certain rule. The main cause of ulcers include: 1. Helicobacter pylori infection 2. Bad diet 3. Mental factors 4. Drug stimulation. Many patients with gastric ulcer who have taken non-steroidal anti-inflammatory drug history, these drugs will stimulate our gastric mucosa, causing damage, then it will cause ulcer disease over time. The current anti-ulcer drug is mainly focused on reducing gastric acid and enhance the protective effect of gastric mucosa. In recent years,the research and development of anti-ulcer drug progress is faster, effective drugs have been listed, sales are also rising.
Antiulcer Drugs,Anti-Ulcerative Agent,Treatment For Stomach Ulcers,Treating Stomach Ulcers,Stomach Ulcer Medicine
Taizhou Volsen Chemical Co., Ltd. , https://www.volsenchem.com